Drug intelligence / Profile preview

chaihu sugan san + zuogui yin

Development stage: Preclinical
Lead developer: First Affiliated Hospital of Xiamen University
Administration: Oral

Overview

Chaihu Sugan San + Zuogui Yin is a combination of two traditional Chinese medicine (TCM) herbal formulas used to treat perimenopausal syndrome, specifically the liver depression and kidney deficiency pattern. Chaihu Sugan San is traditionally used to soothe the liver, regulate qi, and relieve pain, while Zuogui Yin is designed to nourish kidney yin and replenish essence. The combination aims to address the hormonal and psychological symptoms of menopause by balancing the neuroendocrine system and improving emotional well-being. It is currently being evaluated in clinical trials by The First Affiliated Hospital of Xiamen University.

Other names: Chaihu Shugan San + Zuogui YinChaihu Shugan Powder + Zuogui Drink

Targets

ER (Estrogen receptor)

Beyond the preview

Go deeper on chaihu sugan san + zuogui yin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chaihu sugan san + zuogui yin.

Explore the full profile